David J. Fitzgerald
Laboratory of Molecular Biology
The Center for Cancer Research
United States of America
Biography
Dr. Fitzgerald is chief of the Biotherapy Section, Laboratory of Molecular Biology, in the NCI. He received his Ph.D. in 1982 from the University of Cincinnati Medical School, Department of Microbiology. The focus of his Ph.D. dissertation was the endocytic uptake of Pseudomonas exotoxin. He has a longstanding interest in bacterial toxins and their use as therapeutic agents.
Research Interest
Cancer Biology, Cell Biology, Immunology, Microbiology and Infectious Diseases, Molecular Biology and Biochemistry
Publications
-
Antignani A, Sarnovsky R, Fitzgerald DJ (2014) ABT-737 promotes the dislocation of ER luminal proteins to the cytosol, including Pseudomonas exotoxin. Mol. Cancer Ther. 13: 1655-1663.
-
Traini R, Ben-Josef G, Pastrana DV, Moskatel E, Sharma AK, et al. (2010) ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol. Mol. Cancer Ther. 9: 2007-2015.
-
Mansfield E, Amlot P, Pastan I, FitzGerald DJ (1997) Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood. 90: 2020-2026.
-
FitzGerald DJ, Fryling CM, Zdanovsky A, Saelinger CB, Kounnas M, et al. (1995) Pseudomonas exotoxin-mediated selection yields cells with altered expression of low-density lipoprotein receptor-related protein. J. Cell Biol. 129: 1533-1541.
-
Ogata M, Chaudhary VK, Pastan I, FitzGerald DJ (1990) Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol. J. Biol. Chem. 265: 20678-20685.
